login
login

Europe Daily Bulletin No. 8756

28 July 2004
Contents Publication in full By article 36 / 41
ECONOMIC INTERPENETRATION / (eu) pharmaceuticals

US manufacturer of generic medicines MYLAN LABORATORIES will be buying out KING PHARMACEUTICALS in a share exchange transaction valued at USD 4 bn. Under he agreement, KING shareholders will receive 0.9 of a MYLAN common share. The annual turnover estimated for the two entities for the last tax year was around USD 3 bn, with a workforce of 6000.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION